Team

Lindsey Arnold
Senior Associate,
Human Resources &
Operations

Dorothy Lou Bailey
Chief Operating Officer, President
Dorothy Lou Bailey is Chief Operating Officer, President at Exo Therapeutics. She brings over 10 years of experience in creating enduring value for biotech and pharmaceutical companies; including assisting in Exo’s recent Series B raise. Prior to joining Exo, Bailey worked as a corporate development and strategy consultant for VC firms and biotech companies. She also served in positions of increasing responsibility, ultimately as Head of Corporate Development at Blackthorn Therapeutics where she secured a $76 million financing and managed corporate strategy, licensing, search and evaluation. Before Blackthorn, she served as Principal at The Reckon Group, where she closed over $100 million in funding and co-development contracts as well as led new business development and capital strategy within the biopharmaceutical markets. Bailey earned her Bachelors with honors in Biology, Biochemistry & Molecular Genetics from Duke University.
Dorothy Lou Bailey
Chief Operating Officer,
President
Dorothy Lou Bailey
Chief Operating Officer, President
Dorothy Lou Bailey is Chief Operating Officer, President at Exo Therapeutics. She brings over 10 years of experience in creating enduring value for biotech and pharmaceutical companies; including assisting in Exo’s recent Series B raise. Prior to joining Exo, Bailey worked as a corporate development and strategy consultant for VC firms and biotech companies. She also served in positions of increasing responsibility, ultimately as Head of Corporate Development at Blackthorn Therapeutics where she secured a $76 million financing and managed corporate strategy, licensing, search and evaluation. Before Blackthorn, she served as Principal at The Reckon Group, where she closed over $100 million in funding and co-development contracts as well as led new business development and capital strategy within the biopharmaceutical markets. Bailey earned her Bachelors with honors in Biology, Biochemistry & Molecular Genetics from Duke University.

Sumathi Biradar
Cell & Molecular Biology Co-op

Principal Scientist,
Protein Production

Tenghui Chen
Director,
Bioinformatics

JoAnne Drake
Executive Administrator

Scientist I, Biochemistry

Bob Fay
Senior Director,
Facilities Operations

Diana Gikunju
Senior Director,
Biochemistry and
Protein Sciences


Stephanos Ioannidis, PhD
Executive Vice President, Drug Discovery
Dr. Ioannidis has over 20 years of experience in oncology, neuroscience, and inflammation drug development with a particular focus in early discovery to delivery of IND. Prior to joining Exo, Dr. Ioannidis was Executive Vice President, Head of Discovery at IFM Therapeutics where he led the company’s drug discovery group focused on innate immune system therapeutics. Dr. Ioannidis has also held roles of increasing responsibility at H3 Biomedicine, FORMA Therapeutics, and AstraZeneca R&D. Dr. Ioannidis earned his PhD in Synthetic Organic Chemistry from the Imperial College of Science, Technology and Medicine at University of London and completed his postdoctoral fellow at Harvard University.
Stephanos Ioannidis
Executive Vice President,
Discovery
Stephanos Ioannidis, PhD
Executive Vice President, Drug Discovery
Dr. Ioannidis has over 20 years of experience in oncology, neuroscience, and inflammation drug development with a particular focus in early discovery to delivery of IND. Prior to joining Exo, Dr. Ioannidis was Executive Vice President, Head of Discovery at IFM Therapeutics where he led the company’s drug discovery group focused on innate immune system therapeutics. Dr. Ioannidis has also held roles of increasing responsibility at H3 Biomedicine, FORMA Therapeutics, and AstraZeneca R&D. Dr. Ioannidis earned his PhD in Synthetic Organic Chemistry from the Imperial College of Science, Technology and Medicine at University of London and completed his postdoctoral fellow at Harvard University.

Alexandra Joseph
Executive Vice President, Biology
Dr. Joseph has over 20 years of experience in the biotech and pharmaceutical industry, having been responsible for building and overseeing multiple development platforms that have delivered candidates through translational, pre-clinical, and clinical studies. Prior to joining Exo, Dr. Joseph was Vice President of Research at ImmuneID, where she was responsible for building their industry-leading platform for precision therapeutics, resulting in multiple targets and biomarkers being developed for treatments in autoimmune disease. She also previously served as Head of Translational Research at Kiniksa Pharmaceuticals, where she was responsible for the design and implementation of translational research strategy for the company. Prior to that, during her 17-year tenure at Sanofi, Dr. Joseph held positions of increasing responsibility, culminating as Head of Scientific Portfolio Management and Operations, where she established and managed the Global Immunology and Inflammation Research Therapeutic Area and oversaw the discovery pipeline that delivered seven clinical candidates. Dr. Joseph received her PhD in Immunology from Tufts University Graduate School of Biomedical Science and completed her post-doctoral training at the Immune-Mediated Disease Institute at Harvard Medical School. She received a BA in Biology from Santa Clara University in California.
Alexandra Joseph
Executive Vice President, Biology
Dr. Joseph has over 20 years of experience in the biotech and pharmaceutical industry, having been responsible for building and overseeing multiple development platforms that have delivered candidates through translational, pre-clinical, and clinical studies. Prior to joining Exo, Dr. Joseph was Vice President of Research at ImmuneID, where she was responsible for building their industry-leading platform for precision therapeutics, resulting in multiple targets and biomarkers being developed for treatments in autoimmune disease. She also previously served as Head of Translational Research at Kiniksa Pharmaceuticals, where she was responsible for the design and implementation of translational research strategy for the company. Prior to that, during her 17-year tenure at Sanofi, Dr. Joseph held positions of increasing responsibility, culminating as Head of Scientific Portfolio Management and Operations, where she established and managed the Global Immunology and Inflammation Research Therapeutic Area and oversaw the discovery pipeline that delivered seven clinical candidates. Dr. Joseph received her PhD in Immunology from Tufts University Graduate School of Biomedical Science and completed her post-doctoral training at the Immune-Mediated Disease Institute at Harvard Medical School. She received a BA in Biology from Santa Clara University in California.

Shriya Joshi
Principal Research Associate, Biology

Director,
Computational Chemistry

Senior Director,
Medicinal Chemistry

Himanshi Motwani
Data Engineering Co-op

Principal Scientist,
Biology

Vijetha Nagendra Prakash

Unnati Pandya
Senior Scientist I,
Discovery Biology

Alan Saghatelian, PhD
Co-Founder, Interim Chief Executive Officer
Alan Saghatelian, PhD, is a Professor and Frederik Paulsen Chair at the Salk Institute for Biological Studies and an adjunct Professor at the University of California, San Diego.
Dr. Saghatelian has published over 110 papers and six patents. Saghatelian was a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation Fellow. Dr. Saghatelian’s research in chemical biology merges modern analytical techniques with biochemistry and chemical biology to identify genes that regulate fundamental biological pathways and can be targeted for the development of novel therapeutics.
Dr. Saghatelian graduated from the University of California, Los Angeles in 1997 with a degree in Chemistry. He carried out organic and organometallic chemistry research on the total synthesis of a marine natural product with anti-cancer activity in the lab of Professor Craig Merlic. He earned his PhD in Chemistry from The Scripps Research Institute in Chemistry working with Professor Reza Ghadiri. During graduate school, Dr. Saghatelian worked to develop new protein and peptide catalysts through chemical synthesis and protein engineering. Dr. Saghatelian performed his postdoctoral research with Professor Benjamin Cravatt at The Scripps Research Institute where he developed novel mass spectrometry approaches for global metabolite profiling. In 2006, Dr. Saghatelian started his independent career as an Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University, and in 2014, he moved to the Salk Institute for Biological Studies.
Alan Saghatelian, PhD
Co-Founder
Alan Saghatelian, PhD
Co-Founder, Interim Chief Executive Officer
Alan Saghatelian, PhD, is a Professor and Frederik Paulsen Chair at the Salk Institute for Biological Studies and an adjunct Professor at the University of California, San Diego.
Dr. Saghatelian has published over 110 papers and six patents. Saghatelian was a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation Fellow. Dr. Saghatelian’s research in chemical biology merges modern analytical techniques with biochemistry and chemical biology to identify genes that regulate fundamental biological pathways and can be targeted for the development of novel therapeutics.
Dr. Saghatelian graduated from the University of California, Los Angeles in 1997 with a degree in Chemistry. He carried out organic and organometallic chemistry research on the total synthesis of a marine natural product with anti-cancer activity in the lab of Professor Craig Merlic. He earned his PhD in Chemistry from The Scripps Research Institute in Chemistry working with Professor Reza Ghadiri. During graduate school, Dr. Saghatelian worked to develop new protein and peptide catalysts through chemical synthesis and protein engineering. Dr. Saghatelian performed his postdoctoral research with Professor Benjamin Cravatt at The Scripps Research Institute where he developed novel mass spectrometry approaches for global metabolite profiling. In 2006, Dr. Saghatelian started his independent career as an Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University, and in 2014, he moved to the Salk Institute for Biological Studies.

Takashi Satoh
Principal Scientist,
Medicinal Chemistry

Scientist,
Biochemistry

Sai Sundar
Cell & Molecular Biology Co-op

Glenn Van Aller
Principal Scientist,
Biochemistry

Senior Director,
Discovery Biology

Executive Director,
Translational Pharmacology


David Liu, PhD
Broad, HHMI
Founder: Editas, Beam, Prime, Chroma
David R. Liu, PhD, is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator.
Dr. Liu has published over 180 papers and is the inventor of over 70 issued U.S. patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society Pure Chemistry Award, the Arthur C. Cope Young Scholar Award, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. In 2016 he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and in 2017 was named to the Nature’s 10 researchers in the world and to the Foreign Policy Leading Global Thinkers.
Dr. Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors and prime editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing (named one of four 2017 Breakthrough of the Year finalists by Science), prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. He is the scientific founder or co-founder of seven biotechnology and therapeutics companies, including Editas Medicine, Pairwise Plants, Exo Therapeutics, Beam Therapeutics, and Prime Medicine.
Dr. Liu graduated first in his class at Harvard in 1994. He performed organic and bioorganic chemistry research on sterol biosynthesis under Professor E. J. Corey’s guidance as an undergraduate. During his PhD research with Professor Peter Schultz at U. C. Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his PhD in Organic Chemistry from University of California, Berkeley and became Assistant Professor of Chemistry and Chemical Biology at Harvard University in the same year. He was promoted to Associate Professor in 2003 and to Full Professor in 2005. Dr. Liu became a Howard Hughes Medical Institute Investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. Liu has earned several university-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship.
Broad, HHMI
Founder: Editas, Beam, Prime, Chroma
Richard Merkin Professor and Director Merkin Institute Core Institute Member Vice-Chair Faculty, Broad Institute Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences Professor of Chemistry & Chemical Biology, Harvard University

Alan Saghatelian, PhD
Salk Institute
Alan Saghatelian, PhD, is a Professor and Frederik Paulsen Chair at the Salk Institute for Biological Studies and an adjunct Professor at the University of California, San Diego.
Dr. Saghatelian has published over 110 papers and six patents. Saghatelian was a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation Fellow. Dr. Saghatelian’s research in chemical biology merges modern analytical techniques with biochemistry and chemical biology to identify genes that regulate fundamental biological pathways and can be targeted for the development of novel therapeutics.
Dr. Saghatelian graduated from the University of California, Los Angeles in 1997 with a degree in Chemistry. He carried out organic and organometallic chemistry research on the total synthesis of a marine natural product with anti-cancer activity in the lab of Professor Craig Merlic. He earned his PhD in Chemistry from The Scripps Research Institute in Chemistry working with Professor Reza Ghadiri. During graduate school, Dr. Saghatelian worked to develop new protein and peptide catalysts through chemical synthesis and protein engineering. Dr. Saghatelian performed his postdoctoral research with Professor Benjamin Cravatt at The Scripps Research Institute where he developed novel mass spectrometry approaches for global metabolite profiling. In 2006, Dr. Saghatelian started his independent career as an Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University, and in 2014, he moved to the Salk Institute for Biological Studies.
Salk Institute
Professor, Salk Institute
Clayton Foundation Laboratories for Peptide Biology
Dr. Frederik Paulsen Chair

Stuart Schreiber, PhD
Broad Institute
Stuart Schreiber, PhD, is co-Founder of the Broad Institute, a Howard Hughes Medical Institute Investigator, and the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University. His research has been recognized through numerous awards, most recently the Wolf Prize in Chemistry.
Dr. Schreiber’s lab studies the science of therapeutics. Researchers in his group rely on human biology to identify therapeutic targets that have been validated prior to testing in humans, and chemistry and chemical biology to discover small molecules that modulate the targets in ways required to provide relief or protection from disease.
Dr. Schreiber and his group members have discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation) that relate to human disease. Their work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment.
In current research, the Schreiber lab is studying the mechanisms by which cancers resist therapies by exploring a vulnerability of a cell state that group members discovered as central to resistance of many cancers to many therapies. The lab is also studying a novel mechanism our brains use to maintain brain health, and therapeutic agents that enhance the brain-protective mechanism. Each of these studies is supported by efforts to discover small-molecule “binders” that alter functions of proteins by changing their interactomes and lifetimes. The lab is using modern methods of asymmetric synthesis to yield candidate binders bearing DNA barcodes.
He received his BA in Chemistry from the University of Virginia and his PhD in Organic Chemistry from Harvard University.
Broad Institute
Morris Loeb Professor of Chemistry and Chemical Biology
Howard Hughes Medical Institute Investigator

Benjamin Ebert, MD, PhD
DFCI, HHMI
Benjamin Ebert, MD, PhD, is an institute member of the Broad Institute, the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and the chair of medical oncology at the Dana-Farber Cancer Institute. He is also a Howard Hughes Medical Institute investigator.
The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies, with a particular focus on myelodysplastic syndromes (MDS). In large-scale genetic analyses of patient samples, the lab has identified somatic mutations that predict prognosis and response to therapies in MDS patients, characterized a pre-malignant state of hematopoietic cells, and derived the molecular ontogeny of genetic lesions in myeloid malignancies. In addition to human genetic studies, the lab has elucidated the biological basis of transformation of hematopoietic cells by these somatic mutations and developed novel in vivo models to study myeloid malignancies. The lab employs genetic and small molecule screens to identify novel therapeutic targets and small molecules for the treatment of hematologic malignancies and sickle cell disease.
In collaboration with the Broad Institute Proteomics Platform, the Ebert lab elucidated the mechanism of action of lenalidomide, a derivative of thalidomide. Lenalidomide and related drugs modulate the function of an E3 ubiquitin ligase, inducing drug-dependent degradation of specific substrates that are essential for the survival of multiple myeloma and MDS cells, representing the first drugs that bind and modulate the function of an E3 ubiquitin ligase.
Dr. Ebert received a bachelor’s degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an MD from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute before pursuing postdoctoral research at the Broad Institute. Dr. Ebert is an elected member of the National Academy of Medicine.
DFCI, HHMI
George P. Canellos, MD, and Jean S. Canellos Professor of Medicine, Harvard Medical School
Chair of Medical Oncology, DFCI
Investigator, HHMI
Institute Member, Broad Institute of Harvard and MIT

Benjamin Cravatt, PhD
Scripps Research Institute
Benjamin F. Cravatt, PhD, is the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer.
Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a BS in the Biological Sciences and a BA in History. He then received a PhD from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
Scripps Research Insititute
Gilula Chair of Chemical Biology
Professor, Department of Chemistry

Charles Roberts, MD, PhD
St Jude
Charles W. M. Roberts, MD, PhD, is the director of the St. Jude Comprehensive Cancer Center and also serves as an executive vice president and a full member in the Department of Oncology of St. Jude Children’s Research Hospital. Dr. Roberts is a leader in the field of cancer epigenetics, and his research has provided new insights into the central role of chromatin remodeling perturbations in cancer, discoveries that have been translated into investigational therapies for both pediatric and adult cancer patients.
His research specifically focuses on the SWI/SNF (BAF) chromatin remodeling complex. Perturbation of this complex has broad relevance to cancer as at least nine genes that encode SWI/SNF subunits are collectively mutated in over 20% of all cancers. Roberts’ laboratory studies both the mechanisms by which SWI/SNF normally regulates chromatin structure and cell fate, and the mechanisms by which mutation of the complex drives cancer formation. Roberts received his MD from Washington University School of Medicine in St. Louis, Missouri. He completed his pediatric residency and pediatric hematology/oncology fellowship at Boston Children’s Hospital/Dana-Farber Cancer Institute. Roberts has been elected to the Society for Pediatric Research, American Society of Clinical Investigation, and American Pediatric Society.
St Jude
Faculty & Executive Vice President, St Jude Director, Comprehensive Cancer Center Director, Molecular Oncology Division

Laura Kiessling, PhD
The Kiessling Group at Massachusetts Institute of Technology (MIT)
Laura Kiessling, PhD, is the Novartis Professor of Chemistry at the Massachusetts Institute of Technology (MIT) and runs the The Kiessling Group, a lab using chemical biology to elucidate the biological roles of carbohydrates, with a focus on learning new mechanistic concepts.
Understanding carbohydrate function is important as all cells on Earth wear a carbohydrate coat. This carbohydrate coat, termed the glycocalyx, is poised to mediate or modulate diverse and critical biological and medical events. Given the emerging evidence that this coat serves as a critical conduit of information, The Kiessling Group is focused on elucidating how carbohydrates are assembled, how they are recognized, and how they function. Using ideas and approaches that range from synthetic chemistry to molecular and cell biology, the research group is addressing the critical issues at this frontier.
Previously, she was a part of the faculty at the University of Wisconsin–Madison, where she became the Steenbock Professor of Chemistry, the Laurens Anderson Professor of Biochemistry, and the Director of the Keck Center for Chemical Genomics. Dr. Kiessling is a member of the American Academy of Arts & Sciences, the American Academy of Microbiology, the American Philosophical Society, and National Academy of Sciences. She is also the founding Editor-In-Chief of the journal ACS Chemical Biology. She is an author of over 140 peer-reviewed journal articles, an inventor on more than 28 US patents and the recipient of numerous honors and awards.
She received an Sc.B. in Chemistry at Massachusetts Institute of Technology where she performed undergraduate research in organic synthesis with Professor Bill Roush and a PhD in Chemistry at Yale University for her research with Stuart L. Schreiber.
Laura Kiessling, PhD
The Kiessling Group at Massachusetts Institute of Technology (MIT)
Novartis Professor of Chemistry at the Massachusetts Institute of Technology (MIT), The Kiessling Group

Juan Pablo Maianti, PhD
Harvard Chemistry & Chemical Biology
Dr. Maianti has been a leading author in high-impact research publications across multidisciplinary projects in chemistry, biochemistry, pharmacology, genome editing, and target validation, and is a contributor to over a dozen collaborative manuscripts as well as dozens of patents held by Achaogen Inc., Beam Therapeutics, and Exo Therapeutics. For his research contributions to the understanding of the therapeutic benefits of insulin-degrading enzyme (IDE) inhibitors in type-2 diabetes, the discovery of potent exosite-specific substrate-selective IDE inhibitors, and the development of novel broad-spectrum aminoglycoside antibiotics against ESKAPE pathogens, Dr. Maianti has been awarded The Academic Gold Medal from the Governor General of Canada in 2012, the top recognition for Canadian graduates, The Aldrich Graduate Student Innovation Award in 2013, The Knowles Award 2015 from the Gordon Research Conference, and chosen as a Talented 12 nominee by Chemistry & Engineering News in 2016.
Juan Pablo Maianti earned his PhD from Harvard University in Chemistry and Chemical Biology in 2015 under the supervision of Professor David Liu, following a M.Sc. in Synthetic Organic Chemistry under the supervision of Professor Stephen Hanessian at the University of Montreal in 2011, and B.Sc. in Biochemistry from the University of Canterbury in New Zealand.
Harvard Chemistry & Chemical Biology
Assistant Professor, Albert Einstein College of Medicine, C&EN Talented 12 Award, Canada Academic Gold Medal

Novartis Venture Fund
Dr. Aaron Nelson is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he was an investor at dRx Capital, the joint investment company of Novartis and Qualcomm, focused on Digital Medicine. Previously, Aaron worked on technology strategy across multiple Business Units within Novartis, including Strategic Project Leader for the Trials of The Future program and Group Head in the Investigative Toxicology organization. Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institutet, and completed his undergraduate studies at Cornell University.

Newpath Partners
Dr. Cahill is the Founder and Managing Partner of Newpath Partners, a Boston based life science venture fund focused on building therapeutic companies around transformational scientific discoveries. Prior to Newpath, Dr. Cahill worked at Raptor Group where he helped further establish and lead the life-science and technology investment portfolio. Dr. Cahill received both his M.D. and Ph.D. from Duke University. His graduate work, with Professor Robert Lefkowitz (Nobel Laureate), focused on the biophysical and structural properties of cellular receptors and their signaling. His work has led to numerous peer-reviewed publications and awards. He continues to remain active in basic science research. Newpath is a founding investor in most of their life science companies and focuses on uniquely aligning interests between academic scientists, investors, and management teams. Dr. Cahill is directly involved as either a Director or Observer in the following companies: Myeloid Therapeutics, Prime Medicine, Kisbee Therapeutics, Kojin Therapeutics, Chroma Medicine, Exo Therapeutics, and Seven Sense Biosystems. In addition, Dr. Cahill is involved with non-profit and non-partisan groups such as Scientists to Stop COVID-19 (STSC-19) and the Personal Genetics Education Project (pgEd).

Nagesh Mahanthappa, PhD
Founder, Advisor and Interim CEO of Scholar Rock
Nagesh is a consultant and advisor to biotechnology companies, with a particular focus on start-up and early-stage ventures focused on the discovery and development of novel therapeutics. He was mostly recently the founding employee, President and CEO of Scholar Rock, Inc. During his eight-year tenure at Scholar Rock, Nagesh took the company public and lead two distinct drug candidates into clinical testing.
His previous professional experiences include being the founding employee and VP of Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene in early 2012), and was previously a founding employee of Alnylam Pharmaceuticals where he rose to the position of VP, Scientific & Strategic Development. Prior roles include serving as Manager, Business Development at Vertex Pharmaceuticals, and a series of positions with increasing scientific and commercial responsibility at Ontogeny (now a part of Curis, Inc.). Nagesh started in the biotechnology industry as a Staff Scientist at Cambridge NeuroScience, and was a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now a part of Abbott Laboratories).
Nagesh completed his post-doctoral training at E.K. Shriver Center for Mental Retardation (then an affiliate of Massachusetts General Hospital) and Harvard Medical School after receiving his Ph.D. in Neurobiology from the California Institute of Technology. Nagesh received his B.A. in Biology and Chemistry from the University of Colorado, and his M.B.A. from the F.W. Olin Graduate School of Management at Babson College.
Executive Chair

Thilo Schroeder, PhD
Nextech Invest
Thilo has been a leading investor in several precision medicine oncology companies and is a board member of Revolution Medicines (RVMD), PMV Pharma (PMVP), Circle Pharma, Atavistik Bio, MOMA Therapeutics and Silverback Therapeutics (SBTX). Past board seats include Blueprint Medicines (BPMC), Peloton Therapeutics (acquired by Merck), Black Diamond Therapeutics (BDTX), IDEAYA Bioscience (IDYA) and ImaginAb.
Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology now commercialized by Molecular Partners (SWX:MOLN). He also holds a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.
Targeting exosites represents a breakthrough approach to unlocking traditionally intractable targets through highly selective drugs that reprogram target proteins.